Skip to content
Menu

Zenas BioPharma, Inc. ZBIO

Full chart Compare
Set alert

Price alert · ZBIO

All alert types
25.30 USD +0.26 (+1.04%)

As ofNov 20, 2026, 11:32 AM EST

24.62 Day range 25.64
13.50 52-week range 44.60
YTD
-30.32%
1 year
-27.38%

5D -2.53 (-9.18%)

2628FriMonTueWedThu25.04
Market cap
1.72B
Revenue (ttm)
11.00M
EPS (ttm)
-10.08
Shares out
67.82M
Forward P/E
-5.20
YTD return
-30.32%
1-year return
-27.38%
50-day average
28.26
200-day average
25.47
Enterprise value
1.51B
Volume
71.79K
Avg volume
596.65K
Open
24.75
Previous close
25.04
Day's range
24.62 – 25.64
52-week range
13.50 – 44.60
Beta
-0.86
Analysts
Strong Buy
Price target
47.88 (+89.2%)
Earnings date
Mar 15, 2027

Key statistics

Price / sales
154.38
Price / book
7.99
Free cash flow
-250.62M
Total cash
585.31M
Total debt
300.89M
Return on equity
-265.11%
Short % of float
24.14%

Fundamental scorecard

3 of 25 checks passed on ZBIO’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ZBIO Revenue — quarterly 10.00M
ZBIO Net income — quarterly -108.92M
ZBIO EPS — quarterly -1.65

Earnings

ZBIO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 15, 2027Mar 30, 2027-1.36———
Nov 5, 2026Sep 30, 2026-1.24-1.65-0.41-33.06%
Aug 12, 2026Jun 30, 2026-1.12-1.77-0.65-58.04%
May 13, 2026Mar 31, 2026-1.37-1.46-0.09-6.57%
Mar 16, 2026Dec 31, 2025-1.06-4.54-3.48-328.30%
Nov 12, 2025Sep 30, 2025-0.87-1.22-0.35-40.23%

Upgrades / downgrades

ZBIO analyst upgrades and downgrades
DateFirmActionFromTo
Oct 13, 2026HC Wainwright & Co.reitBuyBuy
Sep 30, 2026CitigroupmainBuyBuy
Sep 30, 2026WedbushreitOutperformOutperform
Sep 30, 2026HC Wainwright & Co.reitBuyBuy
Aug 14, 2026Morgan StanleymainEqual-WeightEqual-Weight
Aug 14, 2026GuggenheimreitBuyBuy

About Zenas BioPharma, Inc.

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
zenasbio.com

News

Your note

Sign in to keep a note on ZBIO — it syncs with the Stock Master app.

Insider holders

ZBIO insider holders
InsiderRelationLatest transactionDateShares held
ALLEN PATRICIA LDirectorPurchaseFeb 12, 202619,860
ENRIGHT PATRICK G.DirectorPurchaseOct 8, 20250
FAIRMOUNT FUNDS MANAGEMENT LLCUnknownPurchaseMar 30, 20260
FARMER JOSEPH LPresidentStock Award(Grant)Feb 4, 2026974
FOX JENNIFER AChief Financial OfficerStock Award(Grant)Feb 4, 20261,592
LU HONGBO BDirectorPurchaseMar 30, 20260

Institution ownership

ZBIO institution ownership
Holder% heldSharesValueReported
FMR, LLC14.44%9,792,887245.21MSep 29, 2026
Wellington Management Group, LLP11.94%8,094,339202.68MSep 29, 2026
SR One Capital Management, LP7.43%5,037,854126.15MSep 29, 2026
NEA Management Company, LLC5.93%4,023,219100.74MSep 29, 2026
Blackrock Inc.4.91%3,332,71883.45MSep 29, 2026
Federated Hermes, Inc.4.58%3,107,30877.81MSep 29, 2026

Fund ownership

ZBIO fund ownership
Holder% heldSharesValueReported
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund4.33%2,937,05573.54MJul 30, 2026
SmallCap World Fund Inc4.20%2,849,19871.34MSep 29, 2026
Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund2.69%1,822,56745.64MJul 30, 2026
Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund1.85%1,252,08331.35MJul 30, 2026
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 1.81%1,226,79930.72MSep 29, 2026
Fidelity Select Portfolios-Select Health Care Portfolio1.59%1,080,00027.04MSep 29, 2026